Sentien Announces First Subject Dosed in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19
LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced that the first subject has been enrolled in its [...]
Sentien-Led Team Awarded $2.4M Contract from the U.S. DoD and MTEC
LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, has been awarded a $2.4 million contract from the Medical [...]
Sentien Biotechnologies Announces Open IND in Phase 1/2 Trial of SBI-101 for Patients with COVID-19
LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced that the U.S. Food and Drug Administration (FDA) [...]
Sentien Biotechnologies Names Dr. Allen R. Nissenson as Chief Medical Officer
LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., [...]
Sentien Biotechnologies Names Richard Ganz as Executive Chairman
LEXINGTON, MA – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced the appointment of Richard Ganz as Executive [...]
Sentien Biotechnologies, Inc. Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury
Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced that it has opened enrollment in its Phase 1/2 trial of SBI-101 for [...]
Sentien Biotechnologies, Inc. Announces $12 Million Series A Financing
Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced today that it has closed a $12 million Series A investment round. The [...]
